Mechanism of low-molecular-weight heparin reversal by platelet factor 4

Thrombosis Research

Volumn 124, Issue 1, 2009, Pages 149-155

  Fiore, Martine M ^a   Mackie, Ian M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anticoagulation; Antithrombin; Heparin; Platelet Factor 4

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CALCIUM; EDETIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; PROTEINASE; THROMBIN; THROMBOCYTE FACTOR 4;

ARTICLE; CONCENTRATION (PARAMETERS); PHARMACOKINETICS; PRIORITY JOURNAL; SERODIAGNOSIS;

ANTICOAGULANTS; ANTITHROMBINS; CHELATING AGENTS; COAGULANTS; EDETIC ACID; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KINETICS; MOLECULAR WEIGHT; PLATELET FACTOR 4; PROTAMINES; PROTEIN BINDING; THROMBIN;

EID: 64649084932     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.12.047     Document Type: Article

References (29)

1. Howard A.W., and Aaron S.D. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials. Thromb Haemost 79 (1998) 902-906
2. Samama M.M., and Gerotziafas G.T. Comparative pharmacokinetics of LMWH. Semin Thromb Hemost 26 (2000) 031-038
3. Olson S.T., Swanson R., Raub-Segall E., et al. Accelerating ability of synthetic oligosaccharides on anti-thrombin inhibition of proteinase of the clotting and fibrinolytic systems. Thromb Haemost 92 (2004) 929-939
4. Danielsson A., Raub E., Lindahl U., and Björk I. Role of ternary complexes, in which heparin binds both anti-thrombin and proteinase, in the acceleration of the reactions between anti-thrombin and thrombin of factor Xa. J Biol Chem 261 (1986) 15467-15473
5. Streusand V.J., Björk I., Gettins P.G.W., Petitou M., and Olson S.T. Mechanism of acceleration of anti-thrombin-proteinase reactions by low affinity heparin. J Biol Chem 270 (1995) 9043-9051
6. Rezaie A.R. Calcium enhances heparin catalysis of the anti-thrombin-factor Xa reaction by a template mechanism. J Biol Chem 273 (1998) 16824-16827
7. Rezaie A.R. Heparin chain-length dependence of factor Xa inhibition by anti-thrombin in plasma. Thromb Res 119 (2007) 481-488
8. Gerotziafas G.T., Petropoulou A.D., Verdy E., Samama M.M., and Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 5 (2007) 955-962
9. Padilla A., Gray E., Pepper D.S., and Barrowcliffe T.W. Inhibition of thrombin generation by heparin and low molecular weight heparins in the absence and presence of platelet factor 4. Br J Haematol 82 (1992) 406-413
10. Matthiasson S.E., Lindblad B., and Berqvist D. Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 25 (1995) 124-132
11. Brieger D., and Dawes J. Characterization of persistent anti-Xa activity following administration of the low molecular weight heparin Enoxaparin. Thromb Haemost 72 (1994) 275-280
12. Merlini P.A., Ardissimo D., Bauer K.A., Oltrona L., et al. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arter Thromb Vasc Biol, 17 (1997) 1325-1330
13. Eriksson B.I., Bauer K.A., Lassen M.R., Turpie A.G., et al. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345 (2001) 1298-1304
14. Collignon F., Frydman A., Caplain H., Ozoux M.L., et al. Comparison of the pharmacokinetic profiles of three molecular mass heparins-dalteparin, Enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73 (1995) 6306
15. Mismetti P., Laporte-Simitsidis S., Navarro C., et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 79 (1998) 1162-1165
16. Bara L., Planes A., and Samama M.M. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-thrombin activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, Enoxaparin or Tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 104 (1999) 230-240
17. Depasse F., Gonzalez de Suso M.J., Lagoutte I., Fontcuberta J., Borrell M., and Samama M.M. Comparative study of the pharmacokinetic profiles of two LMWH-Bemiparin and Tinzaparin- administered subcutaneously to healthy male volunteers. Thromb Res 109 (2003) 109-117
18. Mixon T.A., and Dehmer G.J. Recombinant platelet factor 4 for heparin neutralization. Semin Thromb Hemost 30 (2004) 369-377
19. Dehmer G.J., Fisher M., Tate D.A., Teo S., and Bonnem E.M. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 91 (1995) 2188-2194
20. Mayo K.H., Ilyina E., Roongta V., et al. Heparin binding to platelet factor 4. Biochem J 312 (1995) 357-365
21. Denton J., Lane D.A., Thunberg L., Slater A.M., and Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 209 (1983) 455-460
22. Fiore M.M., and Kakkar V.V. Platelet factor 4 neutralizes heparin sulphate-enhanced anti-thrombin inactivation of factor Xa by preventing interaction of enzyme with polysaccharide. Biochem Biophys Res Commun 311 (2003) 71-76
23. Bruffato N., Ward A., and Nesheim M.E. Factor Xa is highly protected from anti-thrombin-Fondaparinux and anti-thrombin-Enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 1 (2003) 1258-1263
24. Matthiasson S.E., Lindblad B., Stjernquist U., and Bergqvist D. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 25 (1995) 203-211
25. Shuman M.A., and Levine S.P. Thrombin generation and secretion of platelet factor 4 during blood clotting. J Clin Invest 63 (1978) 1102-1106
26. Shuman M.A., and Levine S.P. Relationship between secretion of platelet factor 4 and thrombin generation during in vitro blood clotting. J Clin Invest 65 (1980) 307-313
27. Brieger D., and Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 77 (1997) 317-322
28. Yang L., and Rezaie A.R. Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitaminK-dependent coagulation factors. Thromb Haemost 97 (2007) 899-906
29. Rezaie A.R. Identification of basic residues in the heparin-binding exosite of Factor Xa critical for heparin and Factor Va binding. J Biol Chem 275 (2000) 3320-3327